Stage
No active trials
Next date
None yet
Trials
0 active
3 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Drug Drug interactions between NST-1024 and caffeine (and paraxanthine), flurbiprofen, omeprazole, metoprolol, and midazolam”In the company’s words, NCT05368831 on ClinicalTrials.gov
- Tested for
- High Triglycerides, Hypertriglyceridemia
- Main trialPhase 2
- “This is a Phase IIa,multicentre proof of concept study consisting of 2 study periods to study Treatment with NST-1024 as an adjunct to diet to reduce triglyceride (TG) levels in subjects with TG levels of ≥500 mg/dL and ≤2000 mg/dL; determined by percentage change in TG from baseline after 28 days of treatment. The two periods consist of: 1. A 3-week screening period that includes a TG qualifying period, and 2. A 28-days, double-blind, randomized, parallel group, placebo-controlled treatment period. Subjects will return to the study site for a follow-up visit 2 weeks after the last dose.…”In the company’s words, NCT05889156 on ClinicalTrials.gov
Other drugs for High Triglycerides
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Completed | 18 Mar 2025 | Study of the Efficacy and Safety of NST-1024 Versus Placebo in Subjects With Hypertriglyceridemia | |
| Phase 1Completed | 20 Jun 2022 | A Phase 1, First Time in Humans Study of NST-1024 | |
| Phase 1Completed | 7 Sep 2022 | Open-label Study to Evaluate the Effects of NST-1024 on the PK of Multiple Drugs in Healthy Subjects |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026